Back to search

Article

Redirection of SARS-CoV-2 to Phagocytes by Intranasal sACE2-Fc as a Universal Decoy Confers Complete Prophylactic Protection

2025-09-23

Abstract excerpt

<h4>ABSTRACT</h4> The rapid evolution of SARS-CoV-2 and other respiratory RNA viruses limits the success of current vaccines and antibody-based therapies. Engineered decoy receptors based on soluble angiotensin-converting enzyme 2 (sACE2) offer promising alternatives. Clinical-grade recombinant sACE2 inhibits SARS-CoV-2 replication in vitro but shows limited clinical success. This study reports an optimized sACE...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2e353c6b-38d8-5a20-a058-9b4f1843527b
DOI
10.1101/2025.09.23.677998
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Redirection of SARS-CoV-2 to Phagocytes by Intranasal sACE2-Fc as a Universal Decoy Confers Complete Prophylactic ProtectionDOI 10.1101/2025.09.23.677998
An engineered ACE2 decoy receptor can be administered by inhalation and potently targets the BA.1 and BA.2 omicron variants of SARS-CoV-2Semantic proximity
Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activitiesSemantic proximity
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivoSemantic proximity
ACE2 decoy Fc-fusions and bi-specific killer engager (BiKEs) require Fc engagement for <i>in vivo</i> efficacy against SARS-CoV-2Semantic proximity
Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsSemantic proximity
Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection <i>in vitro</i> and <i>in vivo</i>Semantic proximity
Protein Scaffold‐Based Multimerization of Soluble ACE2 Efficiently Blocks SARS‐CoV‐2 Infection In Vitro and In VivoSemantic proximity
Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsSemantic proximity
An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoVSemantic proximity
Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.Semantic proximity
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionSemantic proximity
A recombinant ‘ACE2 Triple Decoy’ that traps and neutralizes SARS-CoV-2 shows enhanced affinity for highly transmissible SARS-CoV-2 variantsSemantic proximity
Select a neighboring publication to make it the new centre.